Abstract:OBJECTIVE:To evaluate the toxicity and efficacy of weekly chemotherapy of paclitaxel and carboplatin with concurrent three dimensional conformal radiotherapy (3D-CRT)for locally advanced non small cell lung cancer(NSCLC).METHODS:From July 2002 to July 2004, a non-randomized prospective study of 52 patients with locally advanced NSCLC treated with 3D-CRT and chemotherapy by paclitaxel and carboplatin were carried out. Of the 52 patients, 21 received concurrent chemoradiation with 3D-CRT and weekly paclitaxel and carboplatin (concurrent chemoradiation group), 31 received sequential chemoradiation with paclitaxel and carboplatin and 3D-CRT (sequential chemoradiation group). In the concurrent chemoradiation group, paclitaxel 40 mg/m2 was administered intravenously for 1 hour. Carboplatin of 1.5 AUC/cycle was used after administration of paclitaxel on D1, D8, D15, D29, D36 and D143. In the sequential chemoradiation group, two cycles of chemotherapy were given at two weeks before radiotherapy. Paclitaxel 150 mg/m2 and carboplatin 5 AUC/cycle were administered on D1 and D21. 3D-CRT was given at two weeks after the second cycle of chemotherapy provided that the hematological examination was normal. 3D-CRT was given at 1.8-2.0 Gy/f to a total dose of 60-66 Gy/6-8 weeks.RESULTS:All the patients completed the trial, but 12 had prolongation of treatment time for more than 1 week due to severe leucopenia with 5 in concurrent chemoradiation group and 7 in sequential chemoradiation group. The rate of complete response (CR), partial response (PR), progress of disease (NC + PD) and overall response was 9.5% (2/21), 71.4% (15/21), 19.0% (4/21) and 81.0%, respectively, in concurrent group, versus 6.5% (2/31), 67.7% (21/31), 25.8% (8/31) and 74.2% in sequential group (CR), respectively. II-III grade of esophagitis, pneumonia and leukocytopenia observed in concurrent chemoradiation group was 61.9% (13/21), 41.9% (13/31) and 23.8% (5/21) ,versus 22.6% (7/31), 42.9 % (9/21) and 19.4% (6/31), respectively, in the sequential chemoradiation group. One of those patients in concurrent chemoradiation group had IV grade of leukocytopenia. The overall median survival time was 17.5 months with 19.0 months for concurrent chemoradiation group, 15.8 months for sequential chemoradiation group. The Overall 1-, 2-year survival rate was 72.0%, 37.0%, respectively and 1 - and 2 - year local control rate was 75.0% and 75.0%.CONCLUSION:Our data indicate that concurrent chemoradiotherapy is safe and effective for locally advanced non small cell lung cancer. Concurrent chemoradiotherapy may be helpful in improving response and survival than sequential one, but no significant difference is observed between two groups in this series(P > 0.05). Further randomized prospective study is still needed to prove it.

Therapeutic effects of concurrent stereotactic radiochemotherapy or surgery plus chemotherapy in stage Ⅲ A non-small cell lung cancer

Concurrent paclitaxel or/and carboplatin with radiotherapy for stageⅢnon-small cell lung cancer

Surgical therapy after concomitant chemo-radiotherapy for stage Ⅲ non-small cell lung cancer

Observation on Curative Effects of Concurrent Radiotherapy and Chemotherapy for Advanced Non-small-cell Lung Cancer

Effects of Concurrent Chemoradiotherapy and Sequential Radiotherapy and Chemotherapy on Progression-free Survival in Patients with Non-small Cell Lung Cancer

Clinical outcome of concurrent chemo-radiotherapy for patients with stage Ⅳ non-small cell lung cancer

Three Dimensional-conformal Radiotherapy Combined Concurrent Chemotherapy with Vinorelbine and Cisplatin for Stage Ⅲ Non-small Cell Lung Cancer

Effect Analysis of Concurrent Chemo-radiotherapy for the Limited-stage Small-cell Lung Cancer

Research of three-dimensional conformal radiotherapy combined with concurrent weekly oxaliplatin for inoperable stage Ⅲ non-small cell lung cancer

A prospective randomized study of adjuvant chemotherapy in completely resected stage ⅢA-N2 non-small cell lung cancer

Concurrent chemoradiotherapy for stage Ⅲ non-small cell lung cancer

Concurrent Albumin-Bound Paclitaxel And/Or Carboplatin With Radiation Therapy For The Treatment Of Locally Advanced Non-Small Cell Lung Cancer

[Weekly Paclitaxel and Carboplatin with Concurrent Three Dimensional Conformal Radiotherapy for Locally Advanced Non Small Cell Lung Cancer].

Concomitant Chemotherapy and Radiotherapy for Inoperable Stage Ⅲ Non-Small Cell Lung Cancer

Curative Effects, Prognostic Factors, and Adverse Reactions of Different Treatment Modalities of Chemotherapy in Patients with Non-Small Cell Lung Cancer

Long-term curative effect of multimodality therapy for non-small cell lung cancer

Late-course three-dimensional conformal concurrent chemoradiotherapy for 31 patients with non-small cell lung carcinoma

Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage IV non-small cell lung cancer: results of a prospective single-center study

P1.16-23 Long-Term Survival Analysis of Surgery in Potential Stereotactic Ablative Radiotherapy Candidates of Non-Small Cell Lung Cancer

[Clinical Trial of Concurrent Low-Dose Chemotherapy Plus Radiation Vs Sequential Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer].

Results of induction chemotherapy followed by three-dimensional conformal radiotherapy and con current weekly paclitaxel for stage Ⅲ non-small cell lung cancer